CEFTAZIDIMA SWYSSI 1g powder for injection / infusion solution medication leaflet

J01DD02 ceftazidime • Antiinfectives for systemic use | Other beta-lactam antibacterials | Third-generation cephalosporins

Ceftazidime is a third-generation cephalosporin antibiotic used to treat severe bacterial infections, including pneumonia, intra-abdominal infections, complicated urinary tract infections, and sepsis. It is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa.

The medication is administered intravenously or intramuscularly, and the dosage is adjusted based on the severity of the infection, the patient's weight, and renal function. Ceftazidime is primarily used in hospitals for complicated infections or for patients at high risk of severe infections.

Patients should be closely monitored during treatment to detect potential side effects, such as allergic reactions, diarrhea, or renal toxicity. It is important for patients to complete the treatment as directed by their doctor.

Side effects may include nausea, diarrhea, skin rashes, or, in rare cases, severe reactions such as encephalopathy or seizures. Patients should inform their doctor of any unusual symptoms.

General data about CEFTAZIDIMA SWYSSI 1g

Substance: ceftazidime

Date of last drug list: 01-02-2025

Commercial code: W70823007

Concentration: 1g

Pharmaceutical form: powder for injection / infusion solution

Quantity: 100

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SWYSSI AG - GERMANIA

Holder: SWYSSI AG - GERMANIA

Number: 15755/2024/07

Shelf life: 3 years-after packing for marketing;Dupa reconstituire-it is used immediately

Concentrations available for ceftazidime

1g, 250mg, 2g, 500mg

Combinations with other substances